The 2025 World Artificial Intelligence Conference was held in Shanghai from July 26th to 28th. The theme of "Working Together in the Intelligent Era" runs through the entire event, bringing a feast of ideas and innovations to the global artificial intelligence field.

As pioneers of AI pharmaceuticals in China, the "Four Little Dragons of AI Pharmaceuticals" are shaping a diverse ecosystem of AI pharmaceuticals in China through differentiated positioning and gradually making a name for themselves in the global market. In this matrix, the four enterprises represent different development paths of China's AI pharmaceutical industry: DeepWise is committed to building a full-chain empowerment platform, Xtalpi excites in "hard technology" infrastructure, Insilico focuses on pipeline innovation driven by generative AI, and Jitai is deeply engaged in the niche field of delivery technology.

China's AI pharmaceutical enterprises are reshaping the global pharmaceutical industry landscape with disruptive power. Their prospects are showing unprecedented prosperity driven by multiple factors such as technological breakthroughs, capital enthusiasm and policy support. As of July 2025, the number of domestic AI pharmaceutical enterprises has reached 108, with 94% concentrated in Beijing, the Yangtze River Delta and the Greater Bay Area. Among them, Beijing, Shanghai and Shenzhen each have more than 20 enterprises, forming a dual highland of technology and industry. The transformation of scientific and technological achievements from universities has become the main force. Enterprises incubated by institutions such as the Chinese Academy of Sciences, Tsinghua University, and Peking University account for nearly half. For instance, leading companies like Xtalpi have deeply bound with multinational pharmaceutical companies through technology licensing. According to the latest forecast, the market size of China's intelligent pharmaceutical industry will exceed 150 billion yuan in 2025 and aim for 400 billion yuan by 2030, with a compound annual growth rate as high as 15% to 20%